GLP-2TZ is the research peptide that introduced an entire generation of laboratories to dual receptor pharmacology in the incretin system. Where earlier compounds engaged only the GLP-1 receptor, GLP-2TZ engages two: GLP-1 and GIP.
If you have read recent metabolic-research literature, you will have seen GLP-2TZ discussed under another name: tirzepatide. The two terms refer to the same research compound. The “TZ” in GLP-2TZ is the same TZ in tirzepatide.
This guide is a plain-English, research-only overview of what GLP-2TZ is, why dual-agonist mechanisms are important to incretin research, and how the peptide compares to single-receptor and triple-receptor compounds in the same family.
What Is GLP-2TZ?
GLP-2TZ is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is the research compound widely referenced in scientific literature as tirzepatide.
Structurally, GLP-2TZ uses a backbone derived from native GIP, modified to engage both GIP and GLP-1 receptors with high affinity. The result is a single molecule that lets researchers study two incretin receptor systems simultaneously, instead of running parallel experiments with separate single-receptor compounds.
ARG Peptides supplies GLP-2TZ in multiple lyophilized research sizes for qualified researchers, including 30mg and 60mg formats.
Why Dual-Agonist Mechanisms Matter
Before GLP-2TZ, the standard incretin research peptide was semaglutide, a pure GLP-1 receptor agonist. Semaglutide research opened the door to studying GLP-1 receptor pharmacology in detail, but it could not address questions involving the GIP receptor in the same molecule.
GLP-2TZ changed that. By engaging both GLP-1R and GIPR with one peptide, it became possible to investigate:
- How the two receptor systems interact when activated simultaneously
- Whether dual-agonist effects differ from the sum of single-agonist effects
- How receptor selectivity and binding affinity influence downstream pathway activation
- Comparative pharmacology between single and dual incretin agonists
This is what made GLP-2TZ / tirzepatide a foundational research tool for the next generation of incretin work, and what set the stage for triple-agonist compounds like retatrutide (GLP-3RT).
GLP-2TZ in the Incretin Research Lineup
To put GLP-2TZ in context with the broader incretin-family research peptide series:
| Compound | Receptor Profile | Generation |
|---|---|---|
| Semaglutide (GLP-1SG) | GLP-1 only | Single agonist |
| Tirzepatide (GLP-2TZ) | GLP-1 + GIP | Dual agonist |
| Retatrutide (GLP-3RT) | GLP-1 + GIP + Glucagon | Triple agonist |
For more direct comparison work, see our Semaglutide vs Tirzepatide research comparison and the follow-up Tirzepatide vs Retatrutide guide.
Structural Notes
GLP-2TZ is built on a 39-amino-acid backbone derived from native GIP, with engineered modifications that extend its circulating half-life and balance its affinity for both GLP-1 and GIP receptors. Like other modern incretin-family research peptides, it is supplied in lyophilized (freeze-dried) form for laboratory storage and reconstitution by qualified researchers.
The “39-amino-acid synthetic peptide” framing is the same one researchers will see for retatrutide / GLP-3RT, because both compounds use similar engineering principles applied to different receptor profiles.
Where GLP-2TZ Fits In Modern Research
GLP-2TZ is relevant for any laboratory studying:
- Incretin receptor pharmacology — investigating how dual GLP-1 / GIP engagement compares to single-receptor activation
- GIP receptor research — using a tool that activates GIPR alongside GLP-1R rather than alone
- Comparative agonist studies — benchmarking dual agonists against single (semaglutide) and triple (retatrutide) compounds
- Receptor crosstalk — understanding signaling interactions when two receptor systems are engaged simultaneously
For laboratories building out an incretin-family reference catalog, GLP-2TZ is widely considered the standard dual-agonist research peptide.
Key Takeaways
- GLP-2TZ and tirzepatide are the same research compound
- It is a dual-receptor agonist acting on the GLP-1 and GIP receptors
- It sits between semaglutide (single GLP-1 agonist) and retatrutide / GLP-3RT (triple GLP-1 + GIP + glucagon agonist) in the incretin research lineup
- Supplied as a lyophilized synthetic peptide for laboratory research use only
For the full incretin-family research catalog, see our research peptide shop. For background context, see our comprehensive peptide guide for researchers.
FOR LABORATORY RESEARCH USE ONLY: ARG Peptides products are research chemicals sold strictly for in vitro and laboratory research. They are not intended for human or animal consumption, and no therapeutic or medical claims are made or implied.